Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of RVT-1801 in patients with sickle cell disease

Trial Profile

Phase I/II study of RVT-1801 in patients with sickle cell disease

Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs RVT 1801 (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors Aruvant Sciences
  • Most Recent Events

    • 07 Dec 2018 New trial record
    • 04 Dec 2018 According to an Aruvant Sciences media release, Punam Malik, MD (physician-scientist at the Cincinnati Children's Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center) is the principal investigator of this trial.
    • 03 Dec 2018 Results presented in the Aruvant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top